Menstrual factors, reproductive history, hormone use, and Urothelial carcinoma risk: A prospective study in the EPIC cohort

Leila Lujan-Barroso, Edoardo Botteri, Saverio Caini, Borje Ljungberg, Nina Roswall, Anne Tjonneland, Bas Bueno-de-Mesquita, Inger T Gram, Rosario Tumino, Lambertus A Kiemeney, Fredrik Liedberg, Tanja Stocks, Marc J Gunter, Neil Murphy, Iris Cervenka, Agnes Fournier, Marina Kvaskoff, Christel Häggström, Kim Overvad, Eiliv LundMarit Waaseth, Renée Turzanski Fortner, Tilman Kühn, Virginia Menéndez, Maria-Jose Sánchez, Carmen Santiuste, Aurora Perez-Cornago, Raul Zamora-Ros, Amanda J Cross, Antonia Trichopoulou, Anna Karakatsani, Eleni Peppa, Domenico Palli, Vittorio Krogh, Veronica Sciannameo, Amalia Mattiello, Salvatore Panico, Carla H van Gils, N Charlotte Onland-Moret, Aurelio Barricarte, Pilar Amiano, Kay-Tee Khaw, Heiner Boeing, Elisabete Weiderpass, Eric J Duell

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Urothelial carcinoma (UC) is the predominant (95%) bladder cancer subtype in industrialised nations. Animal and epidemiological human studies suggest that hormonal factors may influence UC risk.

METHODS: We used an analytic cohort of 333 919 women from the European Prospective Investigation into Cancer and Nutrition Cohort (EPIC). Associations between hormonal factors and incident UC (overall and by tumour grade, tumour aggressiveness, and non-muscle invasive UC) risk were evaluated using Cox proportional hazards models.

RESULTS: During a mean of 15 years of follow-up, 529 women developed UC. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with UC risk (HR≥5vs1=0.48, 0.25-0.90; P-trend in parous women=0.010) and MHT-use (compared to non-use) was positively associated with UC risk (HR=1.27, 1.03-1.57), but no dose-response by years of MHT-use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never-smokers showed similar HR patterns for the number of FTP, while no association between MHT-use and UC risk was observed. Association between MHT-use and UC risk only remained significant in current-smokers. No heterogeneity of the risk estimations in the final model was observed by tumour aggressiveness or by tumour grade. A positive association between the MTH-use and non-muscle invasive UC risk was observed.

CONCLUSIONS: Our results support that increasing the number of FTP may reduce UC risk.

IMPACT: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.

Original languageEnglish
JournalCancer Epidemiology Biomarkers & Prevention
Early online date28 May 2020
DOIs
Publication statusEarly online date - 28 May 2020
Externally publishedYes

Bibliographical note

Copyright ©2020, American Association for Cancer Research.

Fingerprint Dive into the research topics of 'Menstrual factors, reproductive history, hormone use, and Urothelial carcinoma risk: A prospective study in the EPIC cohort'. Together they form a unique fingerprint.

  • Cite this

    Lujan-Barroso, L., Botteri, E., Caini, S., Ljungberg, B., Roswall, N., Tjonneland, A., Bueno-de-Mesquita, B., Gram, I. T., Tumino, R., Kiemeney, L. A., Liedberg, F., Stocks, T., Gunter, M. J., Murphy, N., Cervenka, I., Fournier, A., Kvaskoff, M., Häggström, C., Overvad, K., ... Duell, E. J. (2020). Menstrual factors, reproductive history, hormone use, and Urothelial carcinoma risk: A prospective study in the EPIC cohort. Cancer Epidemiology Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.EPI-20-0184